Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Antibodies have enormous therapeutic and biotechnology potential. G protein-coupled receptors (GPCRs), the main targets in drug development, are of major interest in antibody development programs. Metabotropic glutamate receptors are dimeric GPCRs that can control synaptic activity in a multitude of ways. Here we identify llama nanobodies that specifically recognize mGlu2 receptors, among the eight subtypes of mGluR subunits. Among these nanobodies, DN10 and 13 are positive allosteric modulators (PAM) on homodimeric mGlu2, while DN10 displays also a significant partial agonist activity. DN10 and DN13 have no effect on mGlu2-3 and mGlu2-4 heterodimers. These PAMs enhance the inhibitory action of the orthosteric mGlu2/mGlu3 agonist, DCG-IV, at mossy fiber terminals in the CA3 region of hippocampal slices. DN13 also impairs contextual fear memory when injected in the CA3 region of hippocampal region. These data highlight the potential of developing antibodies with allosteric actions on GPCRs to better define their roles in vivo.

Original publication

DOI

10.1038/s41467-017-01489-1

Type

Journal article

Journal

Nat Commun

Publication Date

06/12/2017

Volume

8

Keywords

Allosteric Regulation, Animals, Binding Sites, Camelids, New World, Cyclic AMP, Cyclopropanes, Fear, Glutamic Acid, Glycine, HEK293 Cells, Hippocampus, Humans, Inositol Phosphates, Male, Mice, Mice, Inbred C57BL, Models, Molecular, Neurons, Receptors, Metabotropic Glutamate, Receptors, Opioid, Single-Domain Antibodies